AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23959152 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 581
Study 23959152 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 581
Study 21352880 — intervention group
Group type: EXPERIMENTAL
Intervention: Netball exercise
Number of subjects: 11
Study 21352880 — intervention group
Group type: COMPARATOR
Intervention: Sedentary period
Number of subjects: 11
Study 18680235 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 1024
Study 18680235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1024
Study 22682553 — intervention group
Group type: COMPARATOR
Intervention: Abciximab with unfractionated heparin (UFH)
Number of subjects: 564
Study 22682553 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 564
Study 15799844 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA group (omeprazole 20 mg bid, clarithromycin 500 mg bid, amoxicillin 1000 mg bid)
Number of subjects: 158
Study 15799844 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 158
Study 15799844 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA group
Number of subjects: 158
Study 15799844 — intervention group
Group type: COMPARATOR
Intervention: OCA group vs Placebo group
Number of subjects: 158
Study 12797399 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) with BCNU
Number of subjects: 176
Study 12797399 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-chemotherapy (Bio-CT) with BCNU
Number of subjects: 176
Study 12797399 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT) without BCNU
Number of subjects: 176
Study 12797399 — intervention group
Group type: COMPARATOR
Intervention: Bio-chemotherapy (Bio-CT) without BCNU
Number of subjects: 176
Study 10760840 — intervention group
Group type: EXPERIMENTAL
Intervention: Deramciclane (0.2 to 50 mg)
Number of subjects: 32
Study 10760840 — intervention group
Group type: COMPARATOR
Intervention: Deramciclane (50 to 150 mg)
Number of subjects: 32
Study 10760840 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethyl deramciclane (active metabolite)
Number of subjects: 32
Study 10760840 — intervention group
Group type: EXPERIMENTAL
Intervention: Deramciclane (all doses)
Number of subjects: 32
Study 7781752 — intervention group
Group type: EXPERIMENTAL
Intervention: regramostim
Number of subjects: 69
Study 7781752 — intervention group
Group type: EXPERIMENTAL
Intervention: molgramostim
Number of subjects: 69
Study 7781752 — intervention group
Group type: EXPERIMENTAL
Intervention: sargramostim
Number of subjects: 69
Study 2194264 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental therapy (specifics not provided)
Number of subjects: 230
Study 2194264 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-sample tests (t and rank-sum)
Number of subjects: 230
Study 2194264 — intervention group
Group type: EXPERIMENTAL
Intervention: O'Brien tests
Number of subjects: 230
Study 619948 — intervention group
Group type: EXPERIMENTAL
Intervention: Motival (fluphenazine 0.5 mg and nortriptyline 10 mg)
Number of subjects: 12
Study 619948 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 12
Study 619948 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 7.5 mg
Number of subjects: 12
Study 619948 — intervention group
Group type: EXPERIMENTAL
Intervention: Motival
Number of subjects: 12
Study 619948 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 12
Study 619948 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 60 mg
Number of subjects: 12
Study 11929322 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg oral dose of rivastigmine
Number of subjects: 11
Study 11929322 — intervention group
Group type: COMPARATOR
Intervention: 2 mg intravenous dose of rivastigmine
Number of subjects: 11
Study 31005287 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin-capecitabine
Number of subjects: 50
Study 31005287 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-carboplatin
Number of subjects: 50
Study 31005287 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin-capecitabine-bevacizumab
Number of subjects: 50
Study 31005287 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-carboplatin-bevacizumab
Number of subjects: 50
Study 30123399 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg)
Number of subjects: 90
Study 30123399 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg)
Number of subjects: 90
Study 30123399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 26832963 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg loading dose and then 20 mg daily until the earliest of 3 days after discharge from intensive care, study day 28, or death)
Number of subjects: 272
Study 26832963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 26832963 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 272
Study 24917661 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose metronidazole (2 grams)
Number of subjects: 226
Study 24917661 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose metronidazole (500 mg twice daily for 7 days)
Number of subjects: 226
Study 24917661 — intervention group
Group type: COMPARATOR
Intervention: ART users
Number of subjects: 226
Study 24917661 — intervention group
Group type: COMPARATOR
Intervention: Non-ART users
Number of subjects: 226
Study 22188832 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV + HAB
Number of subjects: 813
Study 22188832 — intervention group
Group type: COMPARATOR
Intervention: HAB
Number of subjects: 813
Study 22188832 — intervention group
Group type: COMPARATOR
Intervention: HPV
Number of subjects: 813
Study 20151965 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nephrostomy removal
Number of subjects: 22
Study 20151965 — intervention group
Group type: COMPARATOR
Intervention: Tubeless PCNL
Number of subjects: 22
Study 18723319 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (DSE) with Tissue Doppler imaging (TDI)
Number of subjects: 21
Study 18723319 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and gender-matched)
Number of subjects: 21
Study 15939560 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined hormonal therapy (conjugated equine estrogens 0.625 mg/die plus medroxyprogesterone acetate 5 mg/die)
Number of subjects: 103
Study 15939560 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/die
Number of subjects: 103
Study 15939560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 103
Study 12826986 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 200 mg tid
Number of subjects: 271
Study 12826986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg tid
Number of subjects: 271
Study 12826986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 12826986 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 50 mg tid
Number of subjects: 271
Study 10767486 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine
Number of subjects: 100
Study 10895803 — intervention group
Group type: EXPERIMENTAL
Intervention: imipramine/propantheline
Number of subjects: 0
Study 10895803 — intervention group
Group type: EXPERIMENTAL
Intervention: oxybutynin
Number of subjects: 0
Study 10895803 — intervention group
Group type: EXPERIMENTAL
Intervention: penthienate
Number of subjects: 0
Study 1513117 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool temperature dialysis (CTD)
Number of subjects: 6
Study 1513117 — intervention group
Group type: COMPARATOR
Intervention: Regular temperature dialysis (RTD)
Number of subjects: 6
Study 6360431 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg, orally)
Number of subjects: 8
Study 6360431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30577724 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture on oral health education (OHE) given by dentists
Number of subjects: 1053
Study 30577724 — intervention group
Group type: COMPARATOR
Intervention: Lecture on oral health education (OHE) given by school teachers
Number of subjects: 1053
Study 30577724 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1053
Study 30323581 — intervention group
Group type: EXPERIMENTAL
Intervention: YuPingFeng granules (5 g, three times per day for 1 year)
Number of subjects: 240
Study 27068773 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic, theory informed intervention
Number of subjects: 0
Study 27068773 — intervention group
Group type: COMPARATOR
Intervention: Non-participating GPs (locum/part-time GPs)
Number of subjects: 0
Study 27068773 — intervention group
Group type: EXPERIMENTAL
Intervention: Participating GPs
Number of subjects: 0
Study 24442243 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time visual feedback (IG)
Number of subjects: 20
Study 24442243 — intervention group
Group type: COMPARATOR
Intervention: Verbal information from a physiotherapist (CG)
Number of subjects: 20
Study 23208837 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop with standardised teaching material and role playing
Number of subjects: 694
Study 23208837 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 694
Study 20155991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg with simultaneous discontinuation of the current antipsychotic
Number of subjects: 77
Study 20155991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg with tapering off the current antipsychotic over 4 weeks with half the dose after the first 2 weeks
Number of subjects: 77
Study 20155991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg with tapering off the current antipsychotic over 4 weeks after maintenance of the current dose for 2 weeks
Number of subjects: 77
Study 17506781 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg at night
Number of subjects: 75
Study 17506781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 15945343 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel (Taxotere) plus estramustine (Emcyt)
Number of subjects: 0
Study 15945343 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel given every 3 weeks plus prednisone
Number of subjects: 0
Study 11842036 — intervention group
Group type: EXPERIMENTAL
Intervention: 23.5 degrees C exposure in C
Number of subjects: 12
Study 11842036 — intervention group
Group type: COMPARATOR
Intervention: 23.5 degrees C exposure in N
Number of subjects: 12
Study 11842036 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingertip temperature in C
Number of subjects: 12
Study 11842036 — intervention group
Group type: COMPARATOR
Intervention: Fingertip temperature in N
Number of subjects: 12
Study 11842036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold discomfort rating in C
Number of subjects: 12
Study 11842036 — intervention group
Group type: COMPARATOR
Intervention: Cold discomfort rating in N
Number of subjects: 12
Study 10421111 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic CPB (> 35 degrees C)
Number of subjects: 30
Study 10421111 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic CPB (30 degrees C)
Number of subjects: 30
Study 7767514 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,219 20 mg
Number of subjects: 164
Study 7767514 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,219 40 mg
Number of subjects: 164
Study 7767514 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,219 10 mg
Number of subjects: 164
Study 7767514 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,219 100 mg
Number of subjects: 164
Study 7767514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 2082945 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside infusion (n = 10)
Number of subjects: 20
Study 2082945 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol bolus injections of 10 mg every 10 min (n = 10)
Number of subjects: 20
Study 7417129 — intervention group
Group type: EXPERIMENTAL
Intervention: +3Gz acceleration stress
Number of subjects: 10
Study 7417129 — intervention group
Group type: EXPERIMENTAL
Intervention: +5Gz acceleration stress
Number of subjects: 10
Study 7417129 — intervention group
Group type: EXPERIMENTAL
Intervention: +7Gz acceleration stress
Number of subjects: 10
Study 7417129 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall VCG changes during +Gz stress
Number of subjects: 10
Study 7417129 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exposure to +Gz stress
Number of subjects: 10
Study 30635141 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral bovine lactoferrin (150 mg/kg per day; maximum 300 mg/day)
Number of subjects: 2203
Study 30635141 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (same dose as lactoferrin)
Number of subjects: 2203
Study 27844278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 361
Study 27052031 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident Atrial Fibrillation (AF)
Number of subjects: 2753
Study 25225565 — intervention group
Group type: EXPERIMENTAL
Intervention: Filmed modeling
Number of subjects: 46
Study 25225565 — intervention group
Group type: COMPARATOR
Intervention: Tell‐Show‐Do technique (T.S.D)
Number of subjects: 46
Study 21728445 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience (MS)
Number of subjects: 0
Study 21728445 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 19400488 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ketamine infusion combined with spinal anaesthesia
Number of subjects: 12
Study 19400488 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with spinal anaesthesia
Number of subjects: 12
Study 17953336 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus 15 microg of fentanyl (Group 2)
Number of subjects: 75
Study 17953336 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus 25 microg of fentanyl (Group 3)
Number of subjects: 75
Study 17953336 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (Group 1)
Number of subjects: 75
Study 16034041 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 405
Study 16034041 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC)
Number of subjects: 405
Study 11997817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 200
Study 11997817 — intervention group
Group type: EXPERIMENTAL
Intervention: Toupet procedure
Number of subjects: 200
Study 10077414 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 10077414 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 10077414 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem-SR
Number of subjects: 0
Study 10077414 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 10077414 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 10077414 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0
Study 10077414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10077414 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs (when baseline heart rate ≤ 65 beats/min)
Number of subjects: 0
Study 7536623 — intervention group
Group type: EXPERIMENTAL
Intervention: GAGPS (25 mg, 0.5 ml)
Number of subjects: 80
Study 7536623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7536623 — intervention group
Group type: EXPERIMENTAL
Intervention: GAGPS
Number of subjects: 80
Study 2044393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg intramuscularly up to 4-times a day
Number of subjects: 60
Study 2044393 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine 0.3 mg intramuscularly up to 4-times a day
Number of subjects: 60
Study 7195748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin administration
Number of subjects: 0
Study 31914474 — intervention group
Group type: EXPERIMENTAL
Intervention: Large midbody MTL disruption
Number of subjects: 12
Study 31914474 — intervention group
Group type: EXPERIMENTAL
Intervention: Corresponding PMM tears
Number of subjects: 12
Study 31914474 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair of each lesion (MTL and PMM)
Number of subjects: 12
Study 31914474 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL-deficient knees with MTL and PMM lesions
Number of subjects: 12
Study 31914474 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair of meniscal lesions alone in ACL-deficient knees
Number of subjects: 12
Study 30262813 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis CECT 8145 (Ba8145)
Number of subjects: 135
Study 30262813 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat‐killed Bifidobacterium animalis subsp. lactis CECT 8145 (h‐k Ba8145)
Number of subjects: 135
Study 29584910 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (n=98)
Number of subjects: 195
Study 29584910 — intervention group
Group type: COMPARATOR
Intervention: EFV/FTC/TDF (n=97)
Number of subjects: 195
Study 27884851 — intervention group
Group type: EXPERIMENTAL
Intervention: RIC+pPCI
Number of subjects: 139
Study 27884851 — intervention group
Group type: COMPARATOR
Intervention: pPCI alone
Number of subjects: 139
Study 25070483 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, low‐glycemic portion‐controlled diet (PCD) intervention
Number of subjects: 73
Study 25070483 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary care (UDC)
Number of subjects: 73
Study 22515880 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen mix
Number of subjects: 100
Study 22515880 — intervention group
Group type: COMPARATOR
Intervention: Room air/oxygen mix (placebo)
Number of subjects: 100
Study 18562399 — intervention group
Group type: EXPERIMENTAL
Intervention: Exact methods for meta-analyses of safety data
Number of subjects: 700
Study 18562399 — intervention group
Group type: COMPARATOR
Intervention: Asymptotic methods for meta-analyses of safety data
Number of subjects: 700
Study 17633370 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine for supporting healthy energy and strengthening Pi, additional to chemotherapy
Number of subjects: 60
Study 17633370 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 60
Study 15326194 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin-based)
Number of subjects: 5716
Study 15326194 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (single-agent UFT)
Number of subjects: 5716
Study 15326194 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 5716
Study 12399205 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-dose regimen (5 micro g)
Number of subjects: 574
Study 12399205 — intervention group
Group type: COMPARATOR
Intervention: Reduced-dose regimen (2.5 micro g)
Number of subjects: 574
Study 11251757 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication grid intervention
Number of subjects: 836
Study 11251757 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 836
Study 9272813 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 7
Study 9272813 — intervention group
Group type: COMPARATOR
Intervention: Significant nerve injury
Number of subjects: 7
Study 7944415 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter immunoembolization (TIE)
Number of subjects: 14
Study 7944415 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter arterial embolization (TAE)
Number of subjects: 14
Study 2974428 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (200 mg three times a day)
Number of subjects: 49
Study 2974428 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA, 100 mg a day)
Number of subjects: 49
Study 2974428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 2974428 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 49
Study 2974428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian endometriosis
Number of subjects: 49
Study 1426844 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐DTPA solution administered per os or per rectum at a concentration of 1 mmol/L
Number of subjects: 31
Study 1426844 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐DTPA solution
Number of subjects: 31
Study 1426844 — intervention group
Group type: COMPARATOR
Intervention: Plain MR
Number of subjects: 31
Study 1426844 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 31
Study 71447 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte-migration-inhibition tests (L.M.T.) against breast-cancer antigen
Number of subjects: 62
Study 71447 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of breast cancer and/or previous surgery for cystic and proliferative disease
Number of subjects: 62
Study 71447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined presence of epidemiological risk factors and an abnormal mammogram
Number of subjects: 62
Study 30353262 — intervention group
Group type: EXPERIMENTAL
Intervention: Subanesthetic ketamine infusion (0.5 mg/kg over 40 min)
Number of subjects: 61
Study 30353262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 30669411 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat Albumin (WA) 1.5 g
Number of subjects: 20
Study 30669411 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study 30173449 — intervention group
Group type: EXPERIMENTAL
Intervention: № I Empirical Prescription for Chronic Prostatitis (1 dose per day for 8 weeks)
Number of subjects: 53
Study 30173449 — intervention group
Group type: COMPARATOR
Intervention: Saw palmetto extract (160 mg bid for 8 weeks)
Number of subjects: 53
Study 26766797 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser lithotripter
Number of subjects: 77